We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol-Myers, J&J Ink Immunotherapy Research Collaboration
Read MoreHide Full Article
Bristol-Myers Squibb Company (BMY - Free Report) announced a new clinical research collaboration with Johnson & Johnson’s (JNJ - Free Report) Janssen Biotech, Inc., under which its immuno-oncology drug Opdivo will be evaluated in combination with the latter’s Darzalex in phase Ib/phase II studies for multiple myeloma and several solid tumor types.
A look at Bristol-Myers and Johnson & Johnson’s share price movement in the past one year shows that while the former underperformed the Zacks classified Large Cap Pharmaceuticals industry, the latter outperformed the same. Specifically, shares of Bristol-Myers lost 7.9%, while Johnson & Johnson surged 17.8% in comparison to a drop of 1% for the industry.
Performance of BMY & JNJ Vs Large Cap Pharma Industry
The multiple myeloma study will evaluate the safety and tolerability of Darzalex, in combination with Opdivo, with or without Celgene Corporation’s Pomalyst and dexamethasone, in relapsed/refractory multiple myeloma. The solid tumor studies, on the other hand, will evaluate the safety, tolerability and clinical benefit of Darzalex, in combination with Opdivo, in patients with advanced or metastatic tumors, including non-small cell lung, head and neck, pancreatic, colorectal and triple negative breast cancers. While additional tumor types may also be evaluated, the studies are expected to commence this year.
We note that Opdivo is a PD-1 immune checkpoint inhibitor and Darzalex is a CD38-directed cytolytic antibody. A combination of these agents is expected to boost immune-mediated killing of tumors.
We remind investors that Bristol-Myers and Janssen entered into a clinical research collaboration in Jul 2016 to evaluate Opdivo and the latter’s live attenuated double-deleted Listerial monocytogenes cancer immunotherapy, expressing mesothelin and EGFRvIII (JNJ-64041757), in patients with non-small cell lung cancer.
Considering that Bristol-Myers is exploring novel immuno-oncology combination therapies to accelerate the discovery of new treatment options that enable the immune system to fight cancer, the latest deal is encouraging.
Meanwhile, Bristol-Myers is collaborating with several other companies for the evaluation of Opdivo in combination with their cancer regimens. Opdivo recorded worldwide revenues of $2.5 billion in the first nine months of 2016. Label expansion into additional indications should give the drug access to an expanded patient population and increase its commercial potential.
While Bristol-Myers carries a Zacks Rank #2 (Buy), Johnson & Johnson is a Zacks Rank #4 (Sell) stock.
Glaxo’s earnings estimates inched up 0.4% for 2017 over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters, with an average beat of 8.96%. Its share price was up approximately 2% in the past one year.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bristol-Myers, J&J Ink Immunotherapy Research Collaboration
Bristol-Myers Squibb Company (BMY - Free Report) announced a new clinical research collaboration with Johnson & Johnson’s (JNJ - Free Report) Janssen Biotech, Inc., under which its immuno-oncology drug Opdivo will be evaluated in combination with the latter’s Darzalex in phase Ib/phase II studies for multiple myeloma and several solid tumor types.
A look at Bristol-Myers and Johnson & Johnson’s share price movement in the past one year shows that while the former underperformed the Zacks classified Large Cap Pharmaceuticals industry, the latter outperformed the same. Specifically, shares of Bristol-Myers lost 7.9%, while Johnson & Johnson surged 17.8% in comparison to a drop of 1% for the industry.
Performance of BMY & JNJ Vs Large Cap Pharma Industry
The multiple myeloma study will evaluate the safety and tolerability of Darzalex, in combination with Opdivo, with or without Celgene Corporation’s Pomalyst and dexamethasone, in relapsed/refractory multiple myeloma. The solid tumor studies, on the other hand, will evaluate the safety, tolerability and clinical benefit of Darzalex, in combination with Opdivo, in patients with advanced or metastatic tumors, including non-small cell lung, head and neck, pancreatic, colorectal and triple negative breast cancers. While additional tumor types may also be evaluated, the studies are expected to commence this year.
We note that Opdivo is a PD-1 immune checkpoint inhibitor and Darzalex is a CD38-directed cytolytic antibody. A combination of these agents is expected to boost immune-mediated killing of tumors.
We remind investors that Bristol-Myers and Janssen entered into a clinical research collaboration in Jul 2016 to evaluate Opdivo and the latter’s live attenuated double-deleted Listerial monocytogenes cancer immunotherapy, expressing mesothelin and EGFRvIII (JNJ-64041757), in patients with non-small cell lung cancer.
Considering that Bristol-Myers is exploring novel immuno-oncology combination therapies to accelerate the discovery of new treatment options that enable the immune system to fight cancer, the latest deal is encouraging.
Meanwhile, Bristol-Myers is collaborating with several other companies for the evaluation of Opdivo in combination with their cancer regimens. Opdivo recorded worldwide revenues of $2.5 billion in the first nine months of 2016. Label expansion into additional indications should give the drug access to an expanded patient population and increase its commercial potential.
While Bristol-Myers carries a Zacks Rank #2 (Buy), Johnson & Johnson is a Zacks Rank #4 (Sell) stock.
A Stock to Consider
GlaxoSmithKline plc (GSK - Free Report) is another favorably placed stock in this industry, carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Glaxo’s earnings estimates inched up 0.4% for 2017 over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters, with an average beat of 8.96%. Its share price was up approximately 2% in the past one year.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>